🇺🇸 FDA
Patent

US 12274684

Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

granted A61KA61K31/557A61K31/5585

Quick answer

US patent 12274684 (Treatment of vasculopathy with prostacyclin and mesenchymal stem cells) held by United Therapeutics Corporation expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
United Therapeutics Corporation
Grant date
Tue Apr 15 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/557, A61K31/5585, A61K35/28, A61P